Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Supplemental Parenteral Nutrition in Critically Ill Adults: A Pilot Randomised Controlled Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01847534
Recruitment Status : Completed
First Posted : May 7, 2013
Last Update Posted : August 2, 2016
Sponsor:
Collaborator:
Baxter Healthcare Corporation
Information provided by (Responsible Party):
Australian and New Zealand Intensive Care Research Centre

Brief Summary:

One of the essential treatments for assisting patients in their recovery from illness is the provision of nutrition in a liquid form which is delivered into the stomach or as a fluid into the vein. Until recently the benefits of nutrition were undervalued in the critically ill, however, it has now become clear that targeted nutrition can positively affect a person's outcome. This is particularly important for patients who are significantly unwell and require increased amounts of nutrition to support recovery. Inadequate nutrition therapy leads them to rapidly lose weight, predominantly in the form of muscle loss which greatly contributes to their poor recovery.

Whilst nutrition is essential for recovery, there are several issues with the delivery of nutrition via the stomach (the most commonly used method of delivering nutrition in the critically ill). For many reasons, patients are unable to tolerate large quantities of nutrition via the stomach and in addition to this there are hospital or procedural reasons for nutrition being turned off for lengthy periods of time. As such, this results in patients being delivered only about half of the nutrition that is planned. One potential way to overcome this is to deliver nutrition via the vein, whilst nutrition into the stomach continues, with the aim to meet the energy gap that is lost by inadequate nutrition via the stomach.

In this study of 100 patients, we will deliver combined nutrition via the vein and stomach in 50 patients and the other 50 patients will receive nutrition as per normal practice. We will measure important outcomes for these patients to determine if this allows us to meet significantly more of their nutrition needs. This study will also help us determine how best to design a larger study of this strategy.


Condition or disease Intervention/treatment Phase
Multiple Organ Failure Critical Illness Other: Supplemental PN Other: Standard Care Phase 2 Phase 3

Detailed Description:

The principal objectives are:

  1. To determine whether the supplemental Parenteral Nutrition (PN) strategy leads to the delivery of increased amounts of total nutrition (measured as energy delivered), and is safe in regards to adverse effects.
  2. To measure the clinical outcomes in patients receiving both study strategies to provide information to assist design of a larger randomized controlled trial.

    Secondary objectives in a sub-set of patients are:

  3. To determine whether the supplemental PN strategy leads to improved nitrogen balance.
  4. To determine both the nutritional requirements and nutritional intake of critically ill patients during the period of hospitalization after transfer from the Intensive Care Unit (ICU).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Supplemental Parenteral Nutrition in Critically Ill Adults: A Pilot Randomised Controlled Trial
Study Start Date : February 2014
Actual Primary Completion Date : January 2016
Actual Study Completion Date : July 2016

Arm Intervention/treatment
Standard Care
Standard care: Nutrition will be managed as per best practice and local policy including the use of small bowel feeding tubes, prokinetics and PN if required to meet nutrition needs.
Other: Standard Care
Experimental: Supplemental PN

Supplemental PN to complete inadequate EN provision

  1. Patients allocated to the supplemental PN (intervention) group will have PN commenced within 2 hours of randomisation. The starting dose of PN will be determined by the amount of energy received in the 24 hours prior to randomisation.
  2. EN will be managed as per local protocol however EN must not be reduced based on the supplemental PN being administered.
  3. The adequacy of nutrition provision from both PN and EN will be assessed at midday each day for 7 days or until ICU discharge. The dose of PN will be adjusted according to a prespecified schedule.
Other: Supplemental PN



Primary Outcome Measures :
  1. Total energy amount delivered [ Time Frame: First 7 days of the study period ]
    The primary outcome for this pilot study is the total energy amount delivered from nutrition therapy (ie. from Enteral Nutrition (EN) and from supplemental PN, if delivered) over the first 7 days of the study period.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients in intensive care who meet all of the following:

  • Admitted to intensive care between 48 hours and 72 hours previously
  • Mechanically ventilated at the time of enrollment and expected to remain ventilated until the day after tomorrow
  • At least 16 years of age
  • Have central venous access suitable for PN solution administration
  • Have 1 or more organ system failure (respiratory, cardiovascular or renal) related to their acute illness defined as:

    1. Partial pressure of oxygen (PaO2) / Fraction of Inspired oxygen (FiO2) ratio ≤ 300 mmHg
    2. Currently on 1 or more continuous vasopressor infusion which were started at least 4 hours ago at a minimum dose of :

      1. Dopamine greater than 5 mcg/kg/min
      2. Noradrenaline ≥ 0.1mcg/kg/min
      3. Adrenaline ≥ 0.1 mcg/kg/min
      4. Any dose of total vasopressin
      5. Milrinone >0.25mcg/kg/min)
    3. Renal dysfunction defined as

      In patients without known renal disease:

      1. serum creatinine > 171 mmol/l OR
      2. Currently receiving renal replacement therapy

        In patients with known renal disease:

      3. an absolute increase of > 50% in creatinine from baseline OR
      4. Currently receiving renal replacement therapy
    4. Currently has an intracranial pressure monitor or ventricular drain in situ
    5. Currently receiving extracorporeal membrane oxygenation
    6. Currently has a ventricular assist device

Exclusion Criteria:

  • Both EN and PN cannot be delivered at enrollment (i.e. either an enteral tube or a central venous catheter cannot be placed or clinicians feel that EN or PN cannot be safely administered due to any other reason).
  • Currently receiving PN
  • Standard PN solutions cannot be delivered at enrolment (i.e. clinicians believe that a patient definitely needs a specific parenteral nutrition formulation (e.g. glutamine-supplementation or specific lipid formulation).
  • Death is imminent or deemed highly likely in the next 96 hours.
  • There is a current treatment limitation in place or the patient is unlikely to survive to 6 months due to underlying illness
  • More than 80% of energy requirements have been satisfactorily delivered via the enteral route in the last 24 hours.
  • Are known to be pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01847534


Locations
Layout table for location information
Australia, Victoria
The Alfred Hospital
Melbourne, Victoria, Australia, 3004
Australia
Geelong Hospital
Geelong, Australia
New Zealand
Auckland City Hospital (CVICU)
Auckland, New Zealand
Auckland City Hospital (DCCM)
Auckland, New Zealand
Christchurch Hospital
Christchurch, New Zealand
Wellington Hospital
Wellington, New Zealand
Sponsors and Collaborators
Australian and New Zealand Intensive Care Research Centre
Baxter Healthcare Corporation

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Australian and New Zealand Intensive Care Research Centre
ClinicalTrials.gov Identifier: NCT01847534     History of Changes
Other Study ID Numbers: ANZIC RC AD 003
First Posted: May 7, 2013    Key Record Dates
Last Update Posted: August 2, 2016
Last Verified: July 2016

Additional relevant MeSH terms:
Layout table for MeSH terms
Critical Illness
Multiple Organ Failure
Disease Attributes
Pathologic Processes
Shock